网站地图 加入收藏 中文 English
 
首页 中心概况 组织机构 研究队伍 科学研究 人才培养 交流合作 支撑服务 人才招聘 下载专区 联系我们
当前位置:首页 - 交流合作 - 生命科学论坛
生命科学论坛
6月5日清华大学生物论坛 - Prof. Francis Mojica
发布时间:2018-06-03关键字:

 

A comprehensive view of CRISPR

 

Prof. Francis Mojica

Dept. of Genetics, Microbiology and Physiology

Universidad de Alicante, Spain

 

BiographyProf. Mojica pioneered the work that led to the identification of the CRISPR locus, which he named. He also described its biological function as an adaptive immune system in prokaryotes. His work laid the foundations for the development of the revolutionary CRISPR/Cas genome editing technology that has revolutionized the field of Biomedicine. 

Abstract: Arrays of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) were discovered three decades ago. Soon after, during the early 1990s, the first functional analyses were carried in extremely halophilic archaea, where these repeats were shown to interfere with DNA replicon maintenance when manipulated. Afterwards, CRISPR were reported in additional, distantly related prokaryotes, leading to the recognition of a new family of short regularly spaced repeats, widespread in bacteria and archaea. The identification of CRISPR-associated (Cas) proteins and the revelation that repeat-intervening sequences (referred to as spacers) seemed to be incompatible with matching sequences in mobile genetic elements (notably, in viruses, suggesting a defensive function), fueled research on CRISPR-Cas. As a result, their role as an adaptive immune system was soon demonstrated for a variety of model microorganisms, and the mechanism of action unveiled. Subsequently, a three-step (i.e., adaptation, expression and interference) general scheme was conceived, involving the       common elements of active CRISPR-Cas systems: repeats, spacers, Cas proteins and theleadersequences (AT-rich stretches flanking CRISPR arrays). In brief, during adaptation, new spacers are integrated at the leader-proximal end of a CRISPR cassette. Transcription from the leader, and processing of the CRISPR transcript (expression stage), generates single-spacer CRISPR RNA (crRNA) molecules that guide a Cas endonuclease to targeted sequences (complementary to the carried spacer), leading to target cleavage (interference). The unique combination of versatility and feasibility of the diverse CRISPR-Cas components enables a variety of applications, not only in the native carrier organism but also in heterologous (prokaryotic or eukaryotic) hosts. Hitherto, native and engineered interference-related elements of CRISPR-Cas have been harnessed for host immunization, cell dormancy, regulation of gene expression, locus labelling, molecular diagnostics and genome editing, in almost any cell type, from prokaryotes and plant cells to neurons. More recently, the adaptation capability of CRISPR has also been exploited, utilizing the repeat-spacer arrays as data storage devices in bacteria. Thanks to the prokaryotes, we have on our hands the most powerful tools ever available for biological and biomedical research, revolutionizing biotechnology, agriculture and medicine. Still, the use of CRISPR-Cas as therapeutic agents in humans, looks very promising to tackle major challenges in clinical practice.

Time: June 5th, 2018; 10:30-11:30

Venue: New Biology Building, Room 143

Host: Jose C. Pastor-Pareja

举办单位:清华大学生命科学联合中心

 

 

 




版权所有 生命科学联合中心